The article reviews the role of long non-coding RNAs (lncRNAs) in neurodegenerative diseases (NDDs), including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). It highlights the current understanding of lncRNAs' biological functions, molecular mechanisms, and potential therapeutic and diagnostic applications in NDDs. The review emphasizes the involvement of lncRNAs in the pathophysiology of these diseases, such as their role in gene regulation, chromatin remodeling, and inflammation. Specific lncRNAs, like BACE1-AS, NEAT1, MALAT1, and SNHG14, are discussed for their potential as biomarkers and therapeutic targets. The article also explores the use of lncRNAs in diagnostic tools, particularly in blood, plasma, and cerebrospinal fluid, and their potential in silencing adverse lncRNAs to improve symptoms. Finally, it discusses the challenges and future perspectives in the field, emphasizing the need for further research to identify and develop effective lncRNA-based therapies and diagnostics for NDDs.The article reviews the role of long non-coding RNAs (lncRNAs) in neurodegenerative diseases (NDDs), including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). It highlights the current understanding of lncRNAs' biological functions, molecular mechanisms, and potential therapeutic and diagnostic applications in NDDs. The review emphasizes the involvement of lncRNAs in the pathophysiology of these diseases, such as their role in gene regulation, chromatin remodeling, and inflammation. Specific lncRNAs, like BACE1-AS, NEAT1, MALAT1, and SNHG14, are discussed for their potential as biomarkers and therapeutic targets. The article also explores the use of lncRNAs in diagnostic tools, particularly in blood, plasma, and cerebrospinal fluid, and their potential in silencing adverse lncRNAs to improve symptoms. Finally, it discusses the challenges and future perspectives in the field, emphasizing the need for further research to identify and develop effective lncRNA-based therapies and diagnostics for NDDs.